Literature DB >> 9585864

Guidelines to reducing delays in administration of thrombolytic therapy in acute myocardial infarction.

W L Williams1.   

Abstract

The thrombotic coronary accident that triggers a myocardial infarction initiates a 'wavefront' of ischaemic cell death that can be aborted by timely restoration of blood flow. Myocardium destined for necrosis can be salvaged by quick lysis of the culprit clot to restore perfusion, reduce infarct size and save lives. While a number of useful thrombolytic regimens have been investigated, the greatest barrier to optimising efficacy is reducing the delay between the onset of symptoms and administration of thrombolytic therapy. Clinical experience has confirmed laboratory evidence that prompt restoration of coronary blood flow can salvage more than 50% of ischaemic myocardium if achieved within 2 hours. However, after 6 hours of sustained ischaemia, the opportunity to achieve meaningful salvage is largely lost. Analysis of pooled data estimates that for each hour of delay 1.6 fewer lives are saved per 1000 patients treated. Other investigators have estimated 60 to 80 lives saved per 1000 patients treated within 1 hour of symptom onset. More realistically, the time from symptom onset to treatment averages 2.5 to 5 hours in various studies. Reluctance to seek medical help results in a delay of more than 4 hours in at least 40% of patients. There may be some benefits of late, time-independent reperfusion from 12 to 24 hours after symptoms. Some hibernating myocardium may be salvaged resulting in less adverse late ventricular remodelling, reduced infarction expansion and improved electrical stability. Barriers to timely thrombolytic treatment may be classified as presentation delay or treatment delay. Strategies to optimise timely treatment have included pre-hospital administration of thrombolytics. This achieves greatest benefit when used in a more rural setting where transportation times tend to be longer. In this setting, as much as 140 minutes has been shaved off the symptom-to-needle time with a 50% reduction in 3-month mortality sustained as a 30% reduction in 5-year mortality. Most hospitals can improve their treatment (door-to-needle) time by focusing on chronic sources of delay. An emergency room culture of quick, coordinated response to chest pain must involve registration clerks, triage nurses, ECG technicians and emergency physicians. The authority to decide thrombolytic therapy must reside with the primary care physicians in any emergency room that encounters an acute infarction. The profound, life-saving benefits of thrombolytic therapy when used in a timely way should evoke a new sense of urgency in medical personnel when encountering the individual with a potential myocardial infarction.

Entities:  

Mesh:

Year:  1998        PMID: 9585864     DOI: 10.2165/00003495-199855050-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

1.  Timing of coronary recanalization. Paradigms, paradoxes, and pertinence.

Authors:  A J Tiefenbrunn; B E Sobel
Journal:  Circulation       Date:  1992-06       Impact factor: 29.690

2.  Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-08-05       Impact factor: 91.245

3.  Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT).

Authors:  J M Rawles
Journal:  J Am Coll Cardiol       Date:  1997-11-01       Impact factor: 24.094

4.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

5.  Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction.

Authors:  D Gray; N A Keating; J Murdock; A M Skene; J R Hampton
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

6.  Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial.

Authors:  W D Weaver; M Cerqueira; A P Hallstrom; P E Litwin; J S Martin; P J Kudenchuk; M Eisenberg
Journal:  JAMA       Date:  1993-09-08       Impact factor: 56.272

7.  Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy. A GISSI-generated study. GISSI--Avoidable Delay Study Group.

Authors: 
Journal:  Arch Intern Med       Date:  1995-07-24

8.  Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)

Authors:  J Rawles
Journal:  BMJ       Date:  1996-01-27

9.  Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators.

Authors:  L K Newby; W R Rutsch; R M Califf; M L Simoons; P E Aylward; P W Armstrong; L H Woodlief; K L Lee; E J Topol; F Van de Werf
Journal:  J Am Coll Cardiol       Date:  1996-06       Impact factor: 24.094

Review 10.  Time to thrombolytic treatment: factors affecting delay and their influence on outcome.

Authors:  W D Weaver
Journal:  J Am Coll Cardiol       Date:  1995-06       Impact factor: 24.094

View more
  1 in total

1.  Factors associated with longer delays in reperfusion in ST-segment elevation myocardial infarction.

Authors:  Daisy Abreu; M Salomé Cabral; Fernando Ribeiro
Journal:  Int J Cardiol Heart Vessel       Date:  2014-07-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.